Olaparib in gBRCA+ Breast Cancer; 'Clearly Practice Changing'

Longer-term results from the OlympiA trial show a 32% improvement in overall survival with olaparib among women with early-stage germline BRCA-mutated breast cancer.
Medscape Medical News

source https://www.medscape.com/viewarticle/970534?src=rss